National Research Council

The National Research Council appears in the book as part of an earlier, government-led system for scrutinizing drugs with addictive potential. Alongside the Committee on Drug Addiction, it represents a period when preventing risky compounds from reaching the market was a central concern of pharmaceutical research and regulation.

Institutional Role

In retrospect, the author describes the pharmaceutical industry of most of the twentieth century as underdeveloped and dominated by governmental agencies such as the National Research Council and the Committee on Drug Addiction. These bodies brought together university researchers and regulatory gatekeepers. Their energies were directed largely toward preventing new addictive compounds from entering the market, rather than expanding the range of drugs available for commercial use.

A Culture of Caution

That orientation belonged to a broader medical and criminal-justice wariness about treating opioid addiction with another opioid. The long shadow of what researchers regarded as the heroin mistake encouraged interest in opioid antagonists and sustained attention to the risks of introducing addictive drugs. The account situates the National Research Council within this institutional caution, without attributing a particular decision or research finding to the Council alone.

Limits of the Earlier Model

By 1963, progressive researchers were acknowledging that science could not design a perfect cure for addiction. Maintenance drugs, they recognized, would not resolve the problem overnight, given the complexity of international drug trafficking and the psychosocial pain that can lead people to seek relief through drugs. This wider research climate places the Council’s preventive emphasis in context: oversight could seek to limit new sources of harm, but neither regulation nor medication could by itself repair complicated lives or address the forces sustaining addiction.